CN109481495A - 一种治疗糖尿病足的中药复方及其制备方法 - Google Patents
一种治疗糖尿病足的中药复方及其制备方法 Download PDFInfo
- Publication number
- CN109481495A CN109481495A CN201910063430.0A CN201910063430A CN109481495A CN 109481495 A CN109481495 A CN 109481495A CN 201910063430 A CN201910063430 A CN 201910063430A CN 109481495 A CN109481495 A CN 109481495A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine compound
- traditional chinese
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000008159 sesame oil Substances 0.000 claims abstract description 14
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000013871 bee wax Nutrition 0.000 claims abstract description 13
- 239000012166 beeswax Substances 0.000 claims abstract description 13
- 229940116229 borneol Drugs 0.000 claims abstract description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 16
- 239000002674 ointment Substances 0.000 claims description 16
- 235000004256 Buglossoides arvense Nutrition 0.000 claims description 13
- 239000008155 medical solution Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 241000118841 Lithospermum incisum Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 abstract description 15
- 206010052428 Wound Diseases 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 208000008960 Diabetic foot Diseases 0.000 abstract description 8
- 230000008961 swelling Effects 0.000 abstract description 8
- 238000002266 amputation Methods 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010053615 Thermal burn Diseases 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 2
- 230000023597 hemostasis Effects 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000002421 anti-septic effect Effects 0.000 abstract 2
- 230000009756 muscle regeneration Effects 0.000 abstract 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 240000002299 Symphytum officinale Species 0.000 abstract 1
- 235000005865 Symphytum officinale Nutrition 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 13
- 244000157790 Buglossoides arvense Species 0.000 description 11
- 206010040943 Skin Ulcer Diseases 0.000 description 7
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 229960001052 streptozocin Drugs 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 206010017711 Gangrene Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000003790 Foot Ulcer Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010012665 Diabetic gangrene Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000207961 Sesamum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000035357 Focal Infection Diseases 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗糖尿病足的中药复方及其制备方法,涉及中药技术领域,该中药复方是由以下重量份的原料药制成的:紫草9~11份,当归9~11份,甘草9~11份,忍冬藤9~11份,蜂蜡4~6份、冰片4~6份,芝麻油90~110份。本发明的中药复方具有收敛止血,清热解毒,散瘀消肿,疏风通络、防腐生肌之效,在治疗糖尿病足溃疡方面疗效肯定,有效缓解糖尿病足患者的临床症状,促进创面愈合,避免了手术截肢、截趾的苦痛及带来的严重损伤,且能治疗其它伤口日久不愈及各类烧烫伤等,功效显著;同时该中药复方制备方法简单,为外用药,不经口服,不伤及肝肾,解毒抗炎、散瘀消肿、防腐生肌效果显著,无毒副作用。
Description
技术领域
本发明涉及中药技术领域,具体为一种治疗糖尿病足的中药复方及其制备方法。
背景技术
糖尿病足是糖尿病常见的慢性并发症之一,其发病率在不断增长,已成为糖尿病患者致死和致残的主要原因之一。糖尿病足是糖尿病患者由于合并神经病变及各种不同程度末梢血管病变而导致下肢感染、溃疡形成和(或)深部组织的破坏。糖尿病足溃疡与坏疽是糖尿病患者致残、致死的重要原因,同时也是非外伤截肢的首要原因。大量动物实验和临床研究均表明糖尿病足溃疡与坏疽是糖尿病患者致残致死的重要原因,加之其治疗周期长,医疗费用高,给患者和社会带来了沉重的负担,同时糖尿病足也是许多国家非外伤截肢的首要原因,加强对糖尿病足治疗的研究十分必要。
糖尿病足属于中国传统医学“脱疽”、“脉痹”、“消渴”的范畴,中医认识其病因病机多认为是气阴两虚、瘀血痰浊痹阻脉络,又感受湿热邪毒而发。临床上多以辨证论治为原则益气养阴、活血化瘀通络为法。中医药对糖尿病足的外治方法丰富多样,临床上多根据患足的wagner分级及中医证候,确定合适的治疗方法。wagner分级标准如下:0级为有发生足溃疡的危险因素,目前无溃疡;1级为表面有溃疡,临床无感染;2级为较深的溃疡,常合并软组织炎,无脓肿或骨感染;3级为深度感染,伴有骨组织病变或脓肿;4级为局限性坏疽;5级为全足坏疽。迄今为止,现代医学对糖尿病足尚缺乏肯定的治疗方法。
发明内容
本发明的目的是为了解决上述技术的不足,从临床实践出发,选用自拟临床验方,提供疗效好、疗效短、治愈率高,成本低且无毒副作用的一种治疗糖尿病足的中药复方,研究其对糖尿病足的干预作用,减轻患者身心上的痛苦,为糖尿病足的治疗提供实验和临床应用依据。
本发明提供的一种治疗糖尿病足的中药复方,根据中医药理论,利用中药独特的药性,采用紫草、当归、甘草、忍冬藤、蜂蜡、冰片以及芝麻油按照一定的配比要求和独特的工艺制成软膏。
制备本发明中药由以下重量份的原料药制成:紫草9~11份,当归9~11份,甘草9~11份,忍冬藤9~11份,蜂蜡4~6份、冰片4~6份,芝麻油90~110份。
制备工艺:
S1、按照比例称取紫草、当归、甘草以及忍冬藤并混合,将混合物于室温下在芝麻油中浸泡3~4天制得混合药液;
S2、将S1得到的混合药液加热熬制0.5~1h,自然冷却后使用无菌纱布过滤,得到药液;
S3、称取蜂蜡和冰片并加入到S2得到的药液中,搅拌均匀后得到软膏。
上述糖尿病足的中药复方中的中药:
紫草:紫草科紫草属植物的干燥根,具有清热凉血,活血解毒,透疹消斑的功效,具有抗病原微生物的作用以及明显的抗原作用,能够明显抑制肉芽组织增生性炎症,常用于治疗血热毒盛、斑疹紫黑、麻疹不透以及疮疡、湿疹、水火烫伤。
当归:伞形科植物当归的干燥根,具有补血活血、调经补血、润肠通便之功效,能够使血祖细胞增殖、分化,抑制血小板聚焦,降低血液粘滞性,促进血红蛋白以及红细胞的生成等,具有能够降低毛细血管通透性以及抑制PGE2合成或释放的抗炎作用。用于血虚诸证、月经不调、经闭痛经、症瘕结聚以及虚寒腹痛、风湿痹痛、跌扑损伤、痈疽疮疡等的治疗。
忍冬藤:忍冬科植物忍冬的干燥茎枝,具有清热疏风、通络止痛的功效,其所含的木犀草素和木犀草苷等对细菌感染所致的大鼠足肿胀和肉芽增生具有一定的消炎镇痛作用。常用于温热发病、风湿热痹以及关节红肿热痛等症。
甘草:豆科、甘草属多年生草本,根与根状茎粗壮,是一种补益中草药。气微,味甜而特殊。具有补脾益气,清热解毒,缓急止痛,调合诸药之功效。
冰片:龙脑香料植物龙脑香的树脂和挥发油加工品提取获得的结晶,为半透明似梅花瓣块状、片状的晶体,类白色至淡灰棕色,气清香,味清凉,具有开窍醒神,清热解痛,防腐生肌之功,常用于热病神昏,惊痫痰迷,目赤肿痛以及疮疡肿痛,久溃不敛,烧烫伤等的治疗。
蜂蜡:是由蜂群内适龄工蜂腹部的4对蜡腺分泌出来的一种脂肪性物质,黄色或黄棕色,不透明或微透明,表面光滑,体轻,味甘性平。
芝麻油:从芝麻中提炼,具有特别香味,色如琥珀,橙黄微红,晶莹透明,具有延缓衰老、保护血管、润肠通便、减轻烟酒毒害、保护嗓子、治疗鼻炎、减轻异物对食道的损伤以及辅助治疗气管炎等功效。
与现有技术相比,本发明的中药复方及制备方法具有以下有益效果:
1、本发明的治疗糖尿病足的中药复方,基于中医治疗糖尿病足的原理,诸药配伍,具有收敛止血,清热解毒,散瘀消肿,疏风通络、防腐生肌之效,在治疗糖尿病足溃疡方面疗效肯定,有效缓解糖尿病足患者的临床症状,促进创面愈合,避免了手术截肢、截趾的苦痛及带来的严重损伤,且能治疗其它伤口日久不愈及各类烧烫伤等,功效显著。
2、本发明中中药复方的原料简单易得,制备方法简单,为外用药,不经口服,不伤及肝肾,解毒抗炎、散瘀消肿、防腐生肌效果显著,无毒副作用;且换药过程操作简单,换药时以及换药后均无痛苦,适用于工业推广,具有很好的经济效益和广泛的社会效益。
附图说明
图1为高剂量糖尿病足中药复方组给药前和给药后小鼠足部创面照片。
具体实施方式
以下结合具体实施方式对本发明进行详细的描述。需要说明的是,以下实施例中所量取的芝麻油的体积等同质量。
实施例1
一种治疗糖尿病足的中药复方,由下述主要原料制备而成:紫草45g,当归45g,甘草45g,忍冬藤45g,蜂蜡20g、冰片20g,芝麻油450mL。
该中药复方的配置步骤如下:
S1、分别称取紫草、当归、甘草以及忍冬藤并混合,将混合物于室温下在芝麻油中浸泡3天制得混合药液;
S2、将S1得到的混合药液加热熬制0.5h,自然冷却后使用无菌纱布过滤,得到药液;
S3、称取蜂蜡和冰片并加入S2到得到的药液中,搅拌均匀后得到软膏。使用方法:将疼痛处洗净擦干,将本药膏涂于患处,每日早晚各涂抹一次。
实施例2
一种治疗糖尿病足的中药复方,由下述主要原料制备而成:紫草50g,当归50g,甘草50g,忍冬藤50g,蜂蜡25g、冰片25g,芝麻油500mL。
该中药复方的配置步骤如下:
S1、分别称取紫草、当归、甘草以及忍冬藤并混合,将混合物于室温下在芝麻油中浸泡3.5天制得混合药液;
S2、将S1得到的混合药液加热熬制1h,自然冷却后使用无菌纱布过滤,得到药液;
S3、称取蜂蜡和冰片并加入S2到得到的药液中,搅拌均匀后得到软膏。使用方法:将疼痛处洗净擦干,将本药膏涂于患处,每日早晚各涂抹一次。
实施例3
治疗糖尿病足的中药复方,取下述主要原料制备而成:紫草55g,当归55g,甘草55g,忍冬藤55g,蜂蜡30g、冰片30g,芝麻油550mL。
该中药复方的配置步骤如下:
S1、分别称取紫草、当归、甘草以及忍冬藤并混合,将混合物于室温下在芝麻油中浸泡4天制得混合药液;
S2、将S1得到的混合药液加热熬制1h,自然冷却后使用无菌纱布过滤,得到药液;
S3、称取蜂蜡和冰片并加入到S2得到的药液中,搅拌均匀后得到软膏。使用方法:将疼痛处洗净擦干,将本药膏涂于患处,每日早晚各涂抹一次。
以实施例2为例,进行本发明有关药效毒理实验和临床应用情况测试:
一、本发明的一种治疗糖尿病足的中药复方的动物试验
本发明使用的原料均为中草药组分,具有一定的功效,无有毒有害物质,因而其生产的产品对人体无任何毒副作用。
下面以小鼠作为动物试验对象,选择体重为18~22g的昆明种小鼠,SPF级,雌雄各半。
1、试验方法:
1.1糖尿病小鼠模型的建立:取小鼠50只,随机抽取10只为正常对照组,40只为拟糖尿病造模组,向40只造模组小鼠按150mg/kg的比例腹腔注射pH为4.2的柠檬酸缓冲液配制的1%的链脲佐菌素进行造模,向10只正常对照组小鼠腹腔注射等体积不含链脲佐菌素的柠檬酸缓冲液,注射后48h内正常进食,然后再次禁食12h,然后测量空腹血糖值,空腹血糖值≥16.7mmol/L糖尿病模型造模成功;
1.2糖尿病足小鼠模型的建立:以上述正常对照组及造模成功的糖尿病小鼠为造模对象,使用10%的水合氯醛按照3mL/kg的比例腹腔注射麻醉小鼠,待角膜反射消失后在小鼠后背近腿部进行脱毛处理,在外径8mm范围内,用手术刀片和手术剪于同一个部位剪破局部皮肤,裸露筋膜层。次日起每日用50%冰醋酸擦拭皮肤创口1次,连续7天,使创口发生溃疡,造成皮肤溃疡面模型。
1.3动物分组及给药:
正常对照组:不注射链脲佐菌素,没有糖尿病,仅皮肤溃疡造模,造模成功后次日于创口面上外敷芝麻油,每日1次,连续7天;
模型对照组:注射链脲佐菌素,糖尿病造模,皮肤溃疡造模,不使用药物干预;
莫匹罗星软膏组:注射链脲佐菌素,糖尿病造模,皮肤溃疡造模,造模成功后次日于创口面上外敷莫匹罗星软膏,每日1次,连续7天;
低剂量糖尿病足中药复方组:注射链脲佐菌素,糖尿病造模,皮肤溃疡造模,造模成功后次日于创口面上按照0.05g/mL的比例外敷该中药复方制成的软膏,每日1次,连续7天;
高剂量糖尿病足中药复方组:注射链脲佐菌素,糖尿病造模,皮肤溃疡造模,造模成功后次日于创口面上按照0.1g/mL的比例外敷该中药复方制成的软膏,每日1次,连续7天。
1.4散斑全帧实时扫描成像仪检测:采用散斑全帧实时扫描成像仪对病理组织进行的血流动态成像监测,提供动态监测曲线和血流视频记录。把小鼠分别进行10%的水合氯醛的麻醉,然后进行后背近腿部进行脱毛处理,将固定好的小鼠腿部放于激光散斑血流成像仪图像采集处下方开始进行观测。选择足部为观测部位,以长3cm,宽3cm的图像大小进行观察,测定时间为3min,以采样频率23图像/s来进行测定,每次于同一部位选取椭圆形的ROI进行锁定来方便进行观察。选取后2min50s至3min进行标记,以这10秒的血流灌流量的平均值作为检测的ROI部位的血流平均灌流量。
1.5统计方法:使用SPSS17.0统计软件,用“均数±标准差”表示计量资料,其中进行两组间比较时,一般采用t检验法;用单因素方差法进行多组间比较,用LSD方法分析组间两两比较方差齐性,但是方差不齐时用Dunnett’s方法分析。
2、试验结果:
2.1对糖尿病足小鼠下肢微循环的影响:表1为试验小鼠的平均血液灌流量数据,从表1可以看出,与正常对照组比较,模型对照组小鼠下肢血液灌流量明显下降,说明造模成功。与模型对照组比较,低、高剂量糖尿病足中药复方组小鼠下肢平均血液灌流量明显升高(P<0.05或P<0.01)。说明该糖尿病足中药复方能够提高模型小鼠微循环灌注量,改善微循环障碍。
表1 对糖尿病足小鼠足部微循环的影响
与模型组比较*P<0.05**P<0.01
2.2对糖尿病足小鼠足部溃疡愈合的影响
图1为高剂量糖尿病足中药复方组给药前和给药后小鼠足部创面照片。糖尿病足溃疡模型初期表面肢端供血正常或不足,局部水肿,皮肤颜色紫绀、麻木、感觉迟钝或丧失成功当天足的大部或全部感染化脓、坏死,并常波及踝关节及小腿,说明造模成功。从图1可以看出,糖尿病足造模后的小鼠足部创口表面溃烂,且在给药前糖尿病病灶感染已经深入了肌肉组织并引起了局部坏死和肌肉萎缩,在给药后则可明显改善溃疡病变,病灶及肿胀程度均减小,炎症也逐步减轻。说明本发明中的糖尿病足中药复方能够明显改善小鼠糖尿病足溃疡情况,能够缩短溃疡愈合时间,并能够促进创面愈合。
二、本发明的一种治疗糖尿病足的中药复方的临床疗效
1、本方在临床上应用较多,经54例临床观察,取得了较好的治疗效果。
2、诊断标准:有糖尿病病史,早期表现为足部麻木,感觉缺失等。患者对温度、疼痛、压力等的保护觉减弱或者丧失,在有烫伤、异物、创伤等外界因素的作用下,感觉缺失的足就会发生足部溃疡。严重时出现动脉缺血型糖尿病足。这类糖尿病足极易被误诊,导致的后果也最严重。患者由于长期受到高血糖的影响,下肢血管硬化、血管壁增厚、弹性下降,血管内容易形成血栓,并集结成斑块,造成下肢血管闭塞和下肢组织病变。而“足”离心脏最远,缺血现象最严重,从而引发水肿、发黑、腐烂、坏死。
3、用药方法:将上述中药复方制成软膏后涂于患处,每日早、晚2次,涂抹均匀即可。
4、疗效评定:
治愈:临床症状完全消失。
好转:临床症状改善。
未愈:临床症状无改善或加重。
5、治疗效果:本发明中药治疗本病,患者使用后肿胀消失,溃疡面完全愈合或仅局部肿胀,溃疡面缩小30%以上,有效率达到100%。
6、典型病例:
6.1李某,男,72岁,农民,患糖尿病20余年,糖尿病足2年,左脚溃疡坏疽,部分露骨,医院认定以手术截肢治疗,按wagner分级本病属于5级,用本发明糖尿病足中药复方软膏,每天用药两次,坚持每天用药,连续45天后溃疡坏疽痊愈。
2、刘某,女,68岁,工人,患糖尿病10年,糖尿病双足溃疡1年,按wagner分级本病属于4级,用本发明糖尿病足中药复方软膏,每天两次涂抹创面,连续一个月后创面愈合。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (2)
1.一种治疗糖尿病足的中药复方,其特征在于,是由以下重量份的原料药制成的:
紫草9~11份,当归9~11份,甘草9~11份,忍冬藤9~11份,蜂蜡4~6份、冰片4~6份,芝麻油90~110份。
2.根据权利要求1所述的一种治疗糖尿病足的中药复方制成软膏的方法,其特征在于,包括以下步骤:
S1、按比例称取紫草、当归、甘草以及忍冬藤并混合,将混合物于室温下在芝麻油中浸泡3~4天制得混合药液;
S2、将S1得到的混合药液加热熬制0.5~1h,自然冷却后使用无菌纱布过滤,得到药液;
S3、称取蜂蜡和冰片并加入到S2得到的药液中,搅拌均匀后得到软膏。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018102401565 | 2018-03-22 | ||
| CN201810240156.5A CN108186715A (zh) | 2018-03-22 | 2018-03-22 | 一种治疗糖尿病足的中药复方及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109481495A true CN109481495A (zh) | 2019-03-19 |
Family
ID=62595666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810240156.5A Withdrawn CN108186715A (zh) | 2018-03-22 | 2018-03-22 | 一种治疗糖尿病足的中药复方及其制备方法 |
| CN201910063430.0A Pending CN109481495A (zh) | 2018-03-22 | 2019-01-23 | 一种治疗糖尿病足的中药复方及其制备方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810240156.5A Withdrawn CN108186715A (zh) | 2018-03-22 | 2018-03-22 | 一种治疗糖尿病足的中药复方及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108186715A (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110787178A (zh) * | 2019-12-05 | 2020-02-14 | 上海健康医学院 | 木犀草苷的医药用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102441020A (zh) * | 2010-10-08 | 2012-05-09 | 何晓磊 | 一种复方紫草油的配制方法 |
| CN104706713A (zh) * | 2015-02-13 | 2015-06-17 | 常柏 | 一种治疗糖尿病溃疡的中药组合物及其制备方法 |
| CN105381051A (zh) * | 2015-12-10 | 2016-03-09 | 袁明东 | 一种治疗糖尿病足不截肢长期不愈合的中药组合药物及其制备方法 |
-
2018
- 2018-03-22 CN CN201810240156.5A patent/CN108186715A/zh not_active Withdrawn
-
2019
- 2019-01-23 CN CN201910063430.0A patent/CN109481495A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102441020A (zh) * | 2010-10-08 | 2012-05-09 | 何晓磊 | 一种复方紫草油的配制方法 |
| CN104706713A (zh) * | 2015-02-13 | 2015-06-17 | 常柏 | 一种治疗糖尿病溃疡的中药组合物及其制备方法 |
| CN105381051A (zh) * | 2015-12-10 | 2016-03-09 | 袁明东 | 一种治疗糖尿病足不截肢长期不愈合的中药组合药物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 于秀辰: "《糖尿病足》", 30 June 2011, 科学技术文献出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108186715A (zh) | 2018-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751663B (zh) | 一种治疗肛周湿疹的中药外用制剂及其制备方法 | |
| CN106728727A (zh) | 一种治疗疮疡的药膏及其制备方法 | |
| CN103272199B (zh) | 一种治疗冻伤的药物 | |
| CN102861287B (zh) | 一种治疗湿热下注淤血型糖尿病足的中药组合物及其制备方法 | |
| CN102772712B (zh) | 一种治疗热毒炽盛血瘀型糖尿病足的中药组合物 | |
| CN100536886C (zh) | 一种外用治疗痛风的中药组合物 | |
| CN109432245A (zh) | 一种具有祛腐生肌功效的中药组合物,其制剂及应用 | |
| CN104906465A (zh) | 一种治疗妇女慢性盆腔炎的中药化瘀组合物及其制备方法 | |
| CN104524522B (zh) | 一种治疗冻疮的复方软膏 | |
| CN109481495A (zh) | 一种治疗糖尿病足的中药复方及其制备方法 | |
| CN104645122A (zh) | 一种治疗热毒浸淫型褥疮的药物及其制备方法 | |
| CN104587252A (zh) | 一种治疗肾结石的中药组合物 | |
| CN103977367A (zh) | 一种治疗气滞癖血型褥疮的中药及制备方法 | |
| CN103977113A (zh) | 一种治疗糖尿病足的中药 | |
| CN103721138A (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
| CN104971332A (zh) | 一种治疗痔疮中药 | |
| CN117959394B (zh) | 参芪通脉制剂在制备防治糖尿病神经病变药物中的用途 | |
| CN118078894B (zh) | 一种防治痔病术后并发症的中药组合物 | |
| CN102743515B (zh) | 一种治疗烧烫伤的中药膏 | |
| CN105770115A (zh) | 一种治疗湿疹的中药药膏 | |
| CN107412617A (zh) | 一种治疗妊娠外阴湿疹的中药组合物及其制备方法 | |
| CN1709408A (zh) | 一种治疗过敏性紫癜的药 | |
| CN104474452A (zh) | 一种治疗血凝蕴毒型褥疮的药物及其制备方法 | |
| CN105797095A (zh) | 用于防治小腿静脉曲张的中药外洗液 | |
| CN104825629A (zh) | 一种治疗糖尿病足溃疡的中药复方外用涂敷液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190319 |
|
| RJ01 | Rejection of invention patent application after publication |